Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Forsyth

Showing results (401-410 of 406) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 406 results.
Neuro-Oncology|November 11, 2020
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I studySolmaz Sahebjam, Peter A Forsyth, Nam D Tran, et al.
Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Pageof 41

Showing results (401-410 of 406) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 406 results.
Neuro-Oncology|November 11, 2020
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I studySolmaz Sahebjam, Peter A Forsyth, Nam D Tran, et al.
Advances in Radiation Oncology|December 22, 2021
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b StudyKamran A Ahmed, Youngchul Kim, John A Arrington, et al.
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Pageof 41